(ANSA) - ROME, APRIL 11 - DiaSorin announces that it has signed a merger agreement for the acquisition of the American company Luminex Corporation for a constant price of $ 37 per share, equal to an equity value and an enterprise value of approximately 1, 8 billion dollars ".
" We are excited about this transaction which we believe will create value for our shareholders and represents an exceptional opportunity for our future growth, positioning DiaSorine Luminex as a unique combination of diagnostics specialists ", comments the CEO of the DiaSorin group Carlo Rosa .
The board of Diasorin unanimously approved the acquisition of Luminex, listed on the Nasqaq, The price per concordator share represents a premium of about 23.1% compared to the 'unaffected' closing price as of February 24, 2021 (the day before rumors about the possible sale) and at a premium of about 30.6% and about 47.5% compared to the weighted average price on volumes for the period of 30 and 90 days prior to 24 February 2021.
Following the acquisition, the consolidated turnover subase combined for 2020 would be approximately 1.25 billion euros, adjusted EBITDA of approximately 472 million and the positive net financial position of approximately 335 million.
(HANDLE).
